Chemo Hair Loss Device, Peripheral Neuropathy device

Luminate Medical is focused on developing innovative technologies to enhance cancer care, particularly in managing the side effects of treatment. Their flagship products, Lily and Lilac, are designed to address two of the most distressing side effects experienced by cancer patients: hair loss and peripheral neuropathy. The Lily technology employs low-level compression therapy on the scalp to mitigate hair loss during chemotherapy, which is a common and traumatic experience for many patients. Currently, Lily is entering clinical trials in Europe, indicating a commitment to rigorous testing before commercial release.

In addition to hair loss, Luminate Medical's Lilac technology targets chemotherapy-induced peripheral neuropathy (CIPN), a condition that can lead to significant sensory and motor function loss due to nerve damage from chemotherapy. Lilac utilizes flexible low-level compression therapy applied to the hands and feet to help reduce the onset of this debilitating side effect. As Lilac is still in the prototype development phase, Luminate Medical is dedicated to advancing these technologies to improve the quality of life for cancer patients, ensuring they can better manage the challenges associated with their treatment.

Ireland

Luminate Medical is a healthcare technology company that builds devices to make cancer care better for patients by preventing side effects and making at-home treatments a possibility. Based in Galway, Ireland, Luminate is pioneering the development of Lily, a device to prevent chemotherapy induced hair loss in a comfortable and portable way, Lilac, the world's first preventative treatment for peripheral neuropathy, and further pipeline projects enabling remote cancer care. Luminate is a VC-backed startup funded by Y Combinator (S21) with multiple successful grant and investment rounds to date.

Luminate Medical

Company Details